At The Motley Fool, we focus on core investing principles centred around diversification and a long-term mindset.
This largely focuses on quality, blue-chip companies and diversified ASX ETFs.
However, there is no denying that ASX small-caps can be a profitable allocation in any portfolio.
So if you are looking to sprinkle an allocation into ASX small-caps with upside potential, these three have drawn positive attention from brokers following their recent results.
Image source: Getty Images
Oneview Healthcare PLC (ASX: ONE)
Oneview Healthcare provides interactive patient care
The company's Care Experience Platform (CXP) is a unified set of digital tools in a single bedside solution that connects patients, families and care teams with services, education, and information during hospital stays.
A recent report from Bell Potter has indicated ASX small-cap could double in value over the next year.
The company recently released a quarterly report.
Following this, Bell POtter retained its speculative buy recommendation and price target of 45 cents.
From yesterday's closing price of 17.5 cents, this indicates a potential upside of 157%.
Bell Potter did note that while the company expects ~20% growth in live endpoints driven by a strong pipeline, execution risk remains as investors await faster conversion and stronger revenue growth, with valuation unchanged and caution maintained until consistent financial performance is demonstrated.
Despite improving thematics and the need for hospitals to utilise efficiency tools to plug the operating impact of nurse shortages, we remain cautious ahead of more consistent performance on conversion and financial performance.
WRKR Ltd (ASX: WRK)
WRKR is a financial technology company, which engages in the design of innovative overlay capability for banking, wealth management, pensions, and financial services.
It also recently released a quarterly report.
Following the release, Bell Potter reaffirmed buy recommendation, however reduced its share price target to 17.5 cents.
This target is a healthy 57% higher than yesterday's closing price.
The broker noted it was impressed with a reported record cash receipts of $4.3m, including payment of $0.9m outstanding invoices and $0.7m PaidRight customer invoices.
WRK has seen further acceleration in large scale-execution and de-risking. The next quarter is catalyst rich, with transaction revenue expected to scale, balancing investments.
Mach7 Technologies Ltd (ASX: M7T)
This ASX small-cap is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations.
Last week, it released Q3 FY26 results.
This prompted an unchanged buy recommendation from Morgans, with an updated price target of 44 cents per share.
The broker noted a lower operating cost base sets the company up well for better operating leverage from FY27.
From yesterday's closing price of 27.5 cents, this indicates an upside potential of approximately 60%.
